Dr. Kopetz on the Correlation Between Tumor Sidedness and Biomarkers in CRC

preview_player
Показать описание
Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the correlation between tumor sidedness and biomarkers in colorectal cancer.
  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Dr. Kopetz on 0:01:38

Dr. Kopetz on the Correlation Between Tumor Sidedness and Biomarkers in CRC

Dr. Kopetz on 0:01:34

Dr. Kopetz on the Biology of Right- Versus Left-Sided CRC

Dr. Kopetz on 0:01:09

Dr. Kopetz on Updated Data From BEACON CRC Study in BRAF V600E–Mutant CRC

Dr. Kopetz Discusses 0:01:44

Dr. Kopetz Discusses the Treatment of BRAF-Mutant CRC

Dr. Kopetz on 0:01:40

Dr. Kopetz on the Rarity of Fusions in CRC

Dr. Kopetz on 0:01:14

Dr. Kopetz on the Importance of Molecular Testing in CRC

Dr. Kopetz on 0:01:11

Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC

Dr. Kopetz on 0:00:54

Dr. Kopetz on Safety Data From BEACON CRC Trial in BRAF V600E-Mutant mCRC

Dr. Kopetz Discusses 0:01:00

Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC

Colorectal Cancer and 0:32:43

Colorectal Cancer and Immunotherapy with Dr. Scott Kopetz

Fight CRC Kopetz 0:02:57

Fight CRC Kopetz Video

Bringing CTCs to 0:01:46

Bringing CTCs to the forefront of therapeutics

Scott Kopetz, MD, 0:00:30

Scott Kopetz, MD, PhD, FACP, explains how nivolumab is being incorporated into mCRC treatment

In this #DocTalk, 0:59:06

In this #DocTalk, Dr Scott Kopetz from MD Anderson discusses Minimal Residual Disease in CRC

Scott Kopetz, MD, 0:00:38

Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients

Scott Kopetz, MD, 0:01:06

Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC

Do we have 0:24:22

Do we have reliable biomarkers to guide use of immunotherapy agents?

Scott Kopetz, MD, 0:00:58

Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients

Keynote Lecture 4: 0:29:45

Keynote Lecture 4: The BRAF pathway in CRC?

Scott Kopetz, MD, 0:01:35

Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer

Update: Left versus 0:22:50

Update: Left versus right sided colon cancers: Biomarkers versus biology

Targeted Therapies Improve 0:01:10

Targeted Therapies Improve Overall Survival For Patients With Sub Type of Colorectal Caner

Prof Eric Van 1:13:25

Prof Eric Van Cutsem, MD & Scott Kopetz, MD discuss Colorectal Cancer: https://bit.ly/3vfphKP

Expert Highlights Testing 0:01:11

Expert Highlights Testing Standards in Patients With Colorectal Cancer